BerandaLSTA • NASDAQ
add
Lisata Therapeutics Inc
Tutup sebelumnya
$2,82
Rentang hari
$2,86 - $2,94
Rentang tahun
$2,05 - $3,83
Kapitalisasi pasar
23,99Â jt USD
Volume Rata-Rata
15,39Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
NVDA
3,22%
0,35%
0,97%
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Pendapatan | — | — |
Biaya operasional | 5,34Â jt | -10,53% |
Laba bersih | -4,93Â jt | 6,29% |
Margin laba bersih | — | — |
Penghasilan per saham | -0,59 | 9,23% |
EBITDA | -5,29Â jt | 10,53% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 35,86Â jt | -34,08% |
Total aset | 38,20Â jt | -34,24% |
Total liabilitas | 4,76Â jt | -11,55% |
Total ekuitas | 33,44 jt | — |
Saham yang beredar | 8,39 jt | — |
Harga terhadap nilai buku | 0,70 | — |
Tingkat pengembalian aset | -33,03% | — |
Tingkat pengembalian modal | -37,23% | — |
Arus Kas
Perubahan kas bersih
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Laba bersih | -4,93Â jt | 6,29% |
Kas dari operasi | -2,52Â jt | 29,72% |
Kas dari investasi | -6,30Â jt | -151,46% |
Kas dari pembiayaan | 0,00 | 100,00% |
Perubahan kas bersih | -8,78Â jt | -200,53% |
Arus kas bebas | -1,00Â jt | 39,01% |
Tentang
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through the acquisition of Cend Therapeutics by Caladrius Biosciences in September 2022.
In April 2024 the FDA granted their product, certepetide, orphan drug status. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Didirikan
1980
Kantor pusat
Situs
Karyawan
25